Profile data is unavailable for this security.
About the company
Actinogen Medical Limited is an Australia-based biotechnology company. The Company is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The Company is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism is to control elevated levels of cortisol (stress hormone) in the brain through the inhibition of the cortisol synthesis enzyme, 11B-HSD1, without affecting production of cortisol by the adrenal glands, which is essential for the body’s normal functioning. Xanamem is a once-a-day pill designed to deliver high levels of cortisol control in key areas of the brain related to Alzheimer’s and other diseases such as the hippocampus and frontal cortex.
- Revenue in AUD (TTM)685.26k
- Net income in AUD-14.73m
- Incorporated1999
- Employees--
- LocationActinogen Medical LtdSelect HouseSE 901 L 9, 109 Pitt StreetSYDNEY 2000AustraliaAUS
- Phone+61 28964-7401
- Fax+61 28964-7588
- Websitehttps://actinogen.com.au/
